Case Report

Video-Assisted Thoracoscopic Lung Biopsy in Critically Ill Patients With Hematologic Malignancy and Acute Respiratory Distress Syndrome: A Case Series Report

Elizabeth Arrieta, MD1,2, Saveria Sangiovanni, MD1, Juan Esteban Garcia-Robledo, MD1, Mauricio Velásquez, MD1,2, Luz Fernanda Sua, MD, PhD1,2, and Liliana Fernández-Trujillo, MD1,2

Abstract
Pulmonary complications are prevalent among patients with hematologic malignancies, who are at high risk of developing acute respiratory distress syndrome (ARDS). Although diffuse alveolar damage is considered the diagnostic hallmark of ARDS, there are plenty of other non–diffuse alveolar damage etiologies that can mimic ARDS and benefit from a specific therapy, therefore correcting the underlying cause. When the etiology remains unclarified despite noninvasive procedures, a surgical lung biopsy (either open via thoracotomy or video-assisted thoracoscopic surgery [VATS]) may be warranted. However, the role of surgical lung biopsy has not been extensively studied in patients with hematologic malignancy and ARDS and so doubt exists about the risk-benefit relationship of such procedures. In this article, we report a series of 8 critically ill patients with hematologic malignancies and ARDS, who underwent VATS lung biopsy, in a specialized institution in Cali, Colombia, from 2015 to 2019, with special emphasis on its diagnostic yield, modifications in treatment protocol, and safety. VATS lung biopsy is a minimally invasive procedure that appears to be a relatively safe with few postoperative complications and minimal perioperative mortality. It has a high diagnostic yield, resulting in a modification of treatment in a nondepreciable percentage of patients. However, this subset of patients was critically ill, with a high risk of mortality, and the lung biopsy did not appear to affect in this aspect. Future randomized controlled trials are needed to further clarify this topic.

Keywords
hematologic malignancies, acute respiratory distress syndrome, video-assisted thoracoscopic, lung biopsy, case series

Introduction
Pulmonary complications are prevalent among patients with hematologic malignancies,1 who are at high risk of developing acute respiratory distress syndrome (ARDS). The latter is a prevalent and lethal/disabling syndrome, whose etiological diagnosis and treatment is a challenge. ARDS is diagnosed using clinical criteria, specifically the Berlin definition proposed in 2012. However, from a histopathological point of view, diffuse alveolar damage (DAD) is considered the diagnostic hallmark. Nevertheless, there are many other non-DAD etiologies that can present as ARDS and benefit from a specific therapy, which is of relevance since the cornerstone of ARDS treatment is the identification and correction of the underlying cause.2

Reaching a specific diagnosis in this population is challenging due to patient’s instability, variable diagnostic yield of available tools, aberrant response to inflammatory processes, risk-benefit relationship of invasive procedures,1 and so on,

1Fundación Valle del Lili, Cali, Colombia
2Universidad Icesi, Cali, Colombia

Received January 10, 2020. Revised February 10, 2020. Accepted February 13, 2020.

Corresponding Author:
Liliana Fernández-Trujillo, MD, Department of Internal Medicine, Pulmonary Service, Interventional Pulmonology, Avenida Simón Bolívar, Fundación Valle del Lili, Cra 98 No. 18-49, Tower 6, 4th Floor, Cali 760032, Colombia.
Email: liliana.fernandez@fvl.org.co

Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided that the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
which explains why it is typically delayed or not done at all. When the etiology remains unclarified, the most common procedure is to initiate empiric therapy, and although patients tend to respond, there is a small fraction that do not.\(^2,3\) This set of patients may benefit from a surgical lung biopsy, either open via thoracotomy or through video-assisted thoracoscopic surgery (VATS), to guide therapy when noninvasive diagnostic procedures have been performed and uncertainty persists. Although a recent meta-analysis performed with data of critically ill, mechanically ventilated patients showed that open lung biopsy yielded a wide range of diagnosis and that treatment was changed in 78% of subjects,\(^4\) other studies have not been able to show a substantial benefit in this population. Furthermore, the role of surgical lung biopsy has not been extensively studied in patients with hematologic malignancy and ARDS and so doubt exists about the risk-benefit relationship of such procedures.\(^3\)

In this article, we aim to describe a series of 8 critically ill patients with hematologic malignancies and ARDS, who underwent VATS lung biopsy, with special emphasis on its diagnostic yield, modifications in treatment protocol, and safety.

**Methods**

We performed a retrospective analysis of 8 patients with hematologic malignancies and ARDS, who had been admitted to the intensive care unit (ICU) in a specialized institution in Cali, Colombia, from 2015 to 2019, on whom VATS lung biopsy was performed. We included patients with a diagnosis of ARDS using the Berlin criteria, with a thoracic computed tomography (CT) scan showing pulmonary infiltrates, who had negative microbiological and immunological studies, normal bronchoalveolar lavage (BAL), and unremarkable fibrobronchoscopy. Additionally, we had to consider each individual lesion.

**Results**

**Demographic Information**

Patients were admitted to the ICU, most frequently for presenting with acute hypoxic respiratory failure associated with febrile syndrome, febrile neutropenia, or pneumonia (see Table 1 for patients’ overview). Mean age was 47.7 years (SD ±18.16), and APACHE II score at admission was a mean score of 18.6 (SD ±6.7). A thoracic CT scan was performed due to respiratory deterioration showing consolidations in 5 patients, pleural effusion in 5 patients, and ground-glass opacification in 4 patients (Figures 1-4). The most common suspected diagnosis was pneumonia in 6 patients, although alveolar hemorrhage was suspected in 2 patients, progression of oncologic disease with lung compromise in 1 patient, bleomycin toxicity in 1 patient, and septic emboli to the lung from a soft tissue abscess in 1 patient. All but 2 patients were under mechanical ventilation (MV) before the lung biopsy, with a mean time from initiation of MV to lung biopsy of 5.25 days (SD ±4.7). Of the 2 patients without MV prior to lung biopsy, only 1 patient stayed under MV after the procedure for 2 additional days. All of these patients had a complex regimen of antibiotics with or without antivirals and antifungals (Table 2) despite negative cultures, normal BAL, and unremarkable fibrobronchoscopy. Additionally, 5 patients received treatment with corticosteroids. All patients were under MV.

**Surgical Procedure**

The median time from ICU admission to VATS lung biopsy was 6 days (range = 0-30 days). All patients had criteria for ARDS on the day of the lung biopsy, being severe (partial pressure of oxygen/fraction of inspired oxygen \([\text{PaO}_2/\text{FiO}_2] \leq 100 \text{ mm Hg}\) ) in 2 cases, moderate (100 < \([\text{PaO}_2/\text{FiO}_2] \leq 200 \text{ mmHg}\) ) in 5 patients, and mild (200 < \([\text{PaO}_2/\text{FiO}_2] \leq 300 \text{ mm Hg}\) ) in 1 case. Additionally, they had a positive end-expiratory pressure of at least 5 cm H\(_2\)O plus diffuse bilateral pulmonary infiltrates not explained by heart failure or volume overload.

Of the 8 patients, 4 required vasoactive support posterior to the lung biopsy, of which 2 had been already on vasoactive support before the procedure. Surgery had a median time of 35 minutes (range = 18-60 minutes). Three patients received red blood cell transfusion before the lung biopsy due to pan-cytopenia, while none required a transfusion after the procedure. Regarding platelets, 3 patients were transfused before and 1 patient after the biopsy. On the control chest X-ray, 3 patients had small pneumothorax but none had persistent pneumothorax (>48 hours), hemothorax, or hemorrhage that required reintervention. There was no mortality related to the procedure.

**Lung Biopsy Results**

Histopathological diagnosis ranged from bleomycin toxicity in 2 patients, alveolar hemorrhage in 2 patients, organizing pneumonia in 2 patients, DAD in 2 patients, and unspecified interstitial pneumonia in 1 patient. All microbiological cultures were negative (Figures 1-4).

**Outcomes**

After histopathological diagnosis, 6 patients suffered a modification in their treatment.
| Table 1. Patients’ Overview. |
|-----------------------------|
| **Patient 1** | **Patient 2** | **Patient 3** | **Patient 4** | **Patient 5** | **Patient 6** | **Patient 7** | **Patient 8** |
| **Age/sex** | 47/female | 67/male | 17/male | 41/male | 71/male | 55/male | 30/male |
| **Oncologic diagnosis** | Classic Hodgkin lymphoma | Acute lymphoblastic leukemia | Classic Hodgkin lymphoma | Classic Hodgkin lymphoma | Chronic myelocytic leukemia | Bulky follicular lymphoma | Acute lymphoblastic leukemia | Large B-cell lymphoma |
| **ICU admission diagnosis** | • Acute hypoxemic respiratory failure | • Sepsis of unknown origin | • Febrile neutropenia | • Acute hypoxemic respiratory failure | • Severe hemorrhagic cystitis | • Suspected bleomycin toxicity | • Alveolar hemorrhage | • Febrile syndrome |
| **APACHE II score** | 9 | 16 | 21 | 19 | 32 | 20 | 13 | 19 |
| **Organ dysfunction** | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes |
| **Thoracic CT findings** | • Multilobe consolidation | • Diffuse ground-glass opacifications | • Pleural effusion | • Bilateral pleural effusion | • Diffuse infiltrates in the 4 quadrants | • Diffuse ground-glass opacification | • Bilateral pleural effusion | • Ground-glass opacification in LUL with area of consolidation |
| **Pre-biopsy working diagnosis** | Multilobar pneumonia | Septic emboli from soft tissue abscess in right upper extremity with pulmonary superinfection | Multilobar pneumonia, mycotic opportunistic infection, alveolar hemorrhage, and PTLD | Opportunistic infection | Multilobar pneumonia, alveolar hemorrhage | Multilobar pneumonia, diffuse alveolar damage | Fungal pneumonia | Pneumonia versus progression of oncologic disease with lung compromise |
| **Time from ICU admission to LB (days)** | 6 | 18 | 30 | 0 | 6 | 11 | 5 | 4 |
| **LB anatomical site** | Right inferior lobe | Right inferior lobe | Right inferior lobe | Right inferior lobe | Right superior lobe | Left inferior lobe | Left lingula | Right inferior lobe |
| **Surgical time (minutes)** | 35 | 55 | 30 | 60 | 32 | 18 | 30 | 35 |
| **Lung biopsy complications** | No | No | Yes | No | No | Yes | No | No |
| **Pneumothorax** | No | No | No | No | No | No | No | No |
| **Persistent pneumothorax** | No | No | No | No | No | No | No | No |
| **Hemorrhage that required reintervention** | No | No | No | No | No | No | No | No |
| **Mortality related to the procedure** | No | No | No | No | No | No | No | No |
| **Histopathological diagnosis** | Bleomycin toxicity | Unspecified interstitial pneumonia | Organized pneumonia, alveolar hemorrhage | Bleomycin toxicity | Alveolar hemorrhage | Diffuse alveolar damage | Organized pneumonia | Diffuse alveolar damage |
| **Change in patient’s diagnosis** | Yes | Yes | Yes | Yes | No | No | No | Yes |
| **Change in patient’s treatment** | Yes | Yes | Yes | Yes | No | No | No | Yes |
| **Mortality** | Yes | No | No | Yes | No | Yes | Yes | Yes |
| **Cause of death** | Multiorgan failure | N/A | N/A | Multiorgan failure | ARDS fibrotic phase, sepsis | Septic shock | Septic shock | Septic shock |
| **Time from LB to death (days)** | 9 | 33 | 24 | 46 | 34 | 24 | 46 | 34 |

Abbreviations: ICU, intensive care unit; ARDS, acute respiratory distress syndrome; CT, computed tomography; RUL, right upper lobe; LLL, left lower lobe; PTLD, post-transplant lymphoproliferative disorder; LB, lung biopsy.
Most patients had various antimicrobials schemes throughout ICU stay, so the ongoing regime at the time of lung biopsy results was chosen for analysis. Treatment with steroids was changed in 1 patient and initiated in another. Antimicrobials were ceased in 2 patients and narrowed in 2 patients. Prophylactic acyclovir and fluconazole were started in 1 patient. In 2 of the 8 patients, there were no changes executed in management (Tables 2 and 3). Finally, 5 patients died with a median time from lung biopsy to death of 33 days (range = 9-46 days; Table 1).

**Discussion**

Historically, it has been described that patients with hematologic malignancies have poor outcomes when admitted to the ICU. However, recent observational studies have shown improvements in outcomes and availability of treatments, secondary to advances in diagnostic and therapeutic tools. Among the most common causes for ICU admission are respiratory problems, and it is also the most common cause of complication during ICU stay, leading to ARDS in 10% of patients admitted to the ICU and 23% of mechanically ventilated patients as shown in the study by Bellani et al. In this study, mortality reached 46% in patients with severe ARDS. The risk for developing pulmonary infections depends on the degree of immunologic compromise and on patient’s comorbidities and nosocomial exposure, which explains why they are at the highest risk. It is important to highlight the nondepreciable contribution of noninfectious complications that could also lead to ARDS, such as inflammatory disorders, hemorrhage, treatment-related toxicities, recurrent malignancy, and so on. All of these entities require an etiological diagnosis for an optimal therapeutic choice, which remains a challenge in this population. The inability to obtain a specific diagnosis highly increases the exposure to unnecessary drugs, favoring...
adverse effects, bacterial resistance, and negatively affecting patient’s outcomes.\textsuperscript{1}

The diagnostic workup to study diffuse pulmonary infiltrates in the context of ARDS include imaging (chest X-ray or thoracic CT); microbiologic and immunologic investigations of blood, urine, sputum, and endotracheal aspirate; and invasive techniques such as bronchoscopy to perform BAL. The diagnostic challenge relies on the fact that radiographic abnormalities can overlap between different entities, there is limited usefulness and specificity of biomarkers due to abnormal response to inflammatory processes, and diagnostic yield of cultures and bronchoscopy vary widely.\textsuperscript{1}

Concerning bronchoscopy, recent studies showed a great variability in the diagnostic yield for pulmonary infections (between 31% and 74%) in critically ill immunosuppressed patients, probably as a result of delayed sampling time and previous antibiotic use.\textsuperscript{6}

This set of patients, similar to the ones presented in this case series, probably benefit from a lung biopsy to obtain a specific diagnosis. Among surgical lung biopsies, VATS procedures have the advantage of being minimally invasive; reducing bleeding, postoperative complications, and pain-related morbidity; and shortening hospital stay. However, it has been reported in some series that in around 25% of cases, the procedure has to be converted to a thoracotomy to obtain adequate sample tissue, for several reasons including technical problems, instrument issues, surgeon inexperience, and so on.\textsuperscript{9} It has been stated by multiple authors that in capable hands VATS lung biopsy has the same diagnostic yield as open thoracotomy.\textsuperscript{10} Nevertheless, VATS lung biopsy has not been widely studied in this context and further randomized controlled trials are required.

Although DAD is considered the histopathological hallmark in patients with ARDS, several studies have shown that only a fraction of patients have DAD. In a retrospective cohort study conducted by Park et al, 36.9% of patients had DAD, while 63.1% presented with non-DAD, mainly diffuse interstitial lung disease (22.7%) and infection (20.2%).\textsuperscript{11} Another study found interstitial lung disease to be the most

\textbf{Figure 2.} Patient with classic Hodgkin lymphoma. (A) Chest X-ray with bilateral interstitial infiltrates, no evidence of consolidations or pleural effusion. A superior vena cava catheter is observed (R, right side). (B-D) Bleomycin toxicity. Hematoxylin-eosin stain depicting the presence of malformed intra alveolar granulomas, without necrosis or microorganisms. Cultures were negative.
common histopathological finding in 30% of cases, followed by infection in 20%, while DAD was seen in 31.6%. Thus, patients can be subclassified by their histopathological findings in DAD-ARDS and non-DAD-ARDS, which has important implications, as there is no specific therapy for DAD but there could be therapeutic options for non-DAD-ARDS. In our patients, only 2 presented DAD and none had infection. The most common finding was interstitial lung disease (Table 1).

Diagnostic yield, efficacy, and security of surgical lung biopsy, mostly frequently via thoracotomy than VATS, have been analyzed in several observational studies. In our case series, all of the biopsies gave a specific diagnosis and change in management was seen in 6 of the 8 patients. In one study, the diagnostic yield of open lung biopsy in the context of patients with hematologic malignancy was reported at 62%. Its effectiveness, defined as the ability to generate a change in therapy, has been very variable among studies with reports that go from 57% to 94%3,8,12,13; the efficacy obtained in the study performed by Papazian et al indicated that none of the patients received steroids prior to the biopsy.13 A recent meta-analysis that included 95 case series of open lung biopsy reported a change in therapy of 78%, being the most common alterations in the initiation or tailoring of therapy, while discontinuation was seen in 10%.4 In our patients, the alteration in antimicrobial scheme was the most frequent.

The rate of complications reported in the literature is around 30%, in which the most common complication is persistent pneumothorax and initiation or an increase in ventilatory support.3,8,12 One study reported hemorrhagic shock that required reintervention in 2 out of 76 patients.12 Furthermore, the meta-analysis by Wong and Walkey
reported only one case of perioperative mortality from 512 patients analyzed. This is consistent with our patients, in which only mild pneumothoraces were seen in 3 patients, with no persistent pneumothoraces or hemorrhagic complications, despite the fact that several patients had severe anemia and thrombocytopenia that required transfusions prior to the biopsy. In fact, only 1 patient required a platelet transfusion posterior to the biopsy. However, studies analyzing open lung biopsy include both VATS and thoracotomy in contrast with our patients, in whom only VATS was performed.

The most consistent finding throughout the literature is regarding 30-day mortality. To our knowledge, most studies have reported a mortality rate around 50%, and there was no significant difference in mortality between patients who changed their treatment and those who did not. Only in one study, an improvement in mortality was seen in patients who had a specific biopsy diagnosis (infection, malignancy, and inflammatory disease) compared with those with nonspecific findings (interstitial fibrosis, DAD; 5% vs 38%). In our series, mortality rate was higher (5 out of 8 patients) but it was not attributable to VATS lung biopsy since there was no perioperative mortality, but to the advanced and critical stage of their diseases. Furthermore, the procedure did not appear to affect mortality in this set of patients.

A recent meta-analysis comparing BAL and lung biopsy in patients with cancer reported a similar diagnostic yield among the 2 procedures, with noninfectious diagnosis being more common in lung biopsy and infectious diagnosis in BAL. Although change in management occurred more frequently in patients with lung biopsy, complications and mortality were significantly higher in this subset of patients. This is why timing to perform lung biopsy is crucial, and although the optimal time is unknown, there must be a balance between the desire to increase diagnostic yield and performing an invasive procedure that is not without harm.
Table 2. Medical Management Prior to Lung Biopsy.

|               | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 |
|---------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Glucocorticoids | Yes       | Yes       | Yes       | No        | Yes       | Yes       | No        | Yes       |
| (methylprednisolone (pulses)) |            | Methylprednisolone | Hydrocortisone | No | Methylprednisolone | Methylprednisolone | N/A | Methylprednisolone |
| Antibiotics | Yes       | Yes       | Yes       | Yes       | Yes       | Yes       | Yes       | Yes       |
| Vancomycin |            |            | Meropenem | Meropenem | Meropenem | Meropenem | Meropenem | Meropenem |
| Cefepime |            |            | Trimethoprim | Trimethoprim | Trimethoprim | Trimethoprim | Trimethoprim | Trimethoprim |
| Moxifloxacin |            |            | Sulfamethoxazole | Sulfamethoxazole | Sulfamethoxazole | Sulfamethoxazole | Sulfamethoxazole | Sulfamethoxazole |
| Polymixyn B |            |            | Polymixyn B | Polymixyn B | Polymixyn B | Polymixyn B | Polymixyn B | Polymixyn B |
| Antiviral | No        | No        | No        | No        | No        | No        | No        | No        |
| Antifungal | No        | No        | No        | No        | No        | No        | No        | No        |
| Fluconazole |            |            |            |            |            |            |            |            |

Abbreviation: N/A, not available.
Conclusions

Video-assisted thoracoscopic surgery lung biopsy is a minimally invasive procedure that can be done in patients with hematologic malignancy who develop ARDS without a clear etiology. It appears to be a relatively safe procedure with a high histopathological yield, resulting in a modification of treatment in a nondepreciable percentage of patients. Nevertheless, this is a surgical procedure that comes with risks and it should not be done without first exhausting non-invasive/less invasive techniques. Furthermore, although there are minimal mortalities directly related to the procedure, this subset of patients has a high mortality rate, secondary to their underlying disease and critical state, and it is not affected by lung biopsy. Importantly, evidence of this topic comes from observational studies and case series that have major limitations. Further randomized controlled trials are required to obtain solid evidence about the safety and efficacy of thoracoscopic lung biopsy in this subset of patients.

Authors’ Note

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author Contributions

All authors have significantly contributed to the manuscript. EA: Conception and design, manuscript writing and correction, final approval of manuscript. SS: Literature review, manuscript writing and correction, final approval of manuscript. JEGR: Literature review, manuscript writing and correction, final approval of manuscript. MV: Conception and design, manuscript writing and correction, final approval of manuscript. LFS. Conception and design, manuscript writing and correction, final approval of manuscript. LFT: Conception and design, literature review, manuscript writing and correction, final approval of manuscript.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethics Approval

This case series report was prepared in accordance with the ethical standards of the institutional ethics committee and with the 1964 Helsinki Declaration. The Ethics Committee in Biomedical Research (IRB 297-2019) of the Fundación Valle del Lili approved this study.

Informed Consent

Written informed consent was obtained from patients for publication of this case series and any accompanying images.

ORCID iD

Liliana Fernández-Trujillo https://orcid.org/0000-0003-0789-9154

References

1. Harris B, Geyer AI. Diagnostic evaluation of pulmonary abnormalities in patients with hematologic malignancies and hematopoietic cell transplantation. Clin Chest Med. 2017;38:317-331.
2. Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. N Engl J Med. 2017;377;562-572.
3. Donaldson LH, Gill AJ, Hibbert M. The utility of surgical lung biopsy in critically ill patients with diffuse pulmonary infiltrates: a retrospective review. Intern Med J. 2016;46:1306-1310.
4. Wong AK, Walkey AJ. Open lung biopsy among critically ill, mechanically ventilated patients: a metaanalysis. Ann Am Thorac Soc. 2015;12:1226-1230.
5. Al-Zubaidi N, Shehada E, Alshabani K, ZazaDitYafawi J, Kingah P, Soubani AO. Predictors of outcome in patients with hematologic malignancies admitted to the intensive care unit. Hematol Oncol Stem Cell Ther. 2018;11:206-218. doi:10.1016/j.hemonc.2018.03.003
6. Ergan B, Nava S. The use of bronchoscopy in critically ill patients: considerations and complications. Expert Rev Respir Med. 2018;12:651-663. doi:10.1080/17476348.2018.1494576

Table 3. Change in Management After Lung Biopsy.

| Addition y/o change of glucocorticoid | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 8 |
|--------------------------------------|-----------|-----------|-----------|-----------|-----------|-----------|
| No                                   | No        | No        | No        | No        | No        | No        |
| Antimicrobials changed/ceased        | No        | No        | No        | No        | No        | No        |
| Bacterial cover narrowed             | No        | No        | No        | Meropenem vancomycin changed | Meropenem moxifloxacin ceased | Meropenem moxifloxacin ceased |
| Antiviral initiated/ceased           | N/A       | N/A       | N/A       | Meropenem ceased | Meropenem moxifloxacin ceased | Meropenem moxifloxacin ceased |
| Antifungal initiated/ceased          | N/A       | N/A       | N/A       | Meropenem moxifloxacin ceased | Meropenem moxifloxacin ceased | Meropenem moxifloxacin ceased |

Abbreviation: N/A, not available.
7. Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. *JAMA*. 2016;315:788-800.

8. White DA, Wong PW, Downey R. The utility of open lung biopsy in patients with hematologic malignancies. *Am J Respir Crit Care Med*. 2000;161(3 pt 1):723-729.

9. Hsu CP, Hanke I, Douglas JM Jr. Diagnostic video-assisted thoracoscopic procedures. *Ann Surg*. 1995;222:626-631.

10. Gal AA. Use and abuse of lung biopsy. *Adv Anat Pathol*. 2005;12:192-202.

11. Park J, Lee YJ, Lee J, et al. Histopathologic heterogeneity of acute respiratory distress syndrome revealed by surgical lung biopsy and its clinical implications. *Korean J Intern Med*. 2018;33:532-540.

12. Almotairi A, Biswas S, Shahin J. The role of open lung biopsy in critically ill patients with hypoxic respiratory failure: a retrospective cohort study. *Can Respir J*. 2016;2016:8715024. doi:10.1155/2016/8715024

13. Papazian L, Thomas P, Bregeon F, et al. Open lung biopsy in patients with acute respiratory distress syndrome. *Anesthesiology*. 1998;88:935-944.

14. Chellappandian D, Lehrnbecher T, Phillips B, et al. Bronchoalveolar lavage and lung biopsy in patients with cancer and hematopoietic stem cell transplantation recipients: a systematic review and meta-analysis. *J Clin Oncol*. 2015;33:501-509. doi:10.1200/JCO.2014.58.0480

15. Palakshappa JA, Meyer NJ. Which patients with ARDS benefit from lung biopsy? *Chest*. 2015;128:1073-1082.